Frontlight ResearchEarly access
Active, not recruitingNo phase
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
Key facts
- Who runs it
- Prime Medicine, Inc.
- Where
- Ann Arbor, Boston, Chicago, Los Angeles, New Haven, Sacramento, and San Antonio, United StatesSee the 7 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 30 people, planned
- Started
- 29 Dec 2025
- Expected to end
- Dec 2027
- Type of study
- Observational
- Record updated
- 12 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Confirmed Wilson Disease (WD) as determined by the following criteria:; An established clinical diagnosis of WD; Genetic analysis confirming the presence of biallelic pathogenic variants at ATP7B, at least one of which is EITHER p.H1069Q OR p.R778L OR Participants without a confirmed genetic diagnosis may enroll only with explicit approval from the Medical Monitor
Who cannot take part
- Prior history of gene therapy, liver transplantation, hepatocyte (cellular) transplantation, or active listing for liver transplantation
- Significant neurological conditions within the prior 12 months which may impact participant safety or participation in the study, including ability to complete study requirements or procedures as outlined in the clinical study protocol
- Prior or active malignancy or myeloproliferative disorder (excluding Stage 1 or lower, fully treated/excised malignant and pre-malignant disease of the skin, cervix or colon. Additionally, any other malignant and pre-malignant disease that the Investigator in consultation with the treating oncologist and study Medical Monitor deem has been fully treated/excised for > 5 years)
- In patients with psychiatric involvement, current or fluctuant clinical instability with new or changing diagnoses or substantial medication regimen changes in the past 12 months that could limit their participation, in the opinion of the Investigator
- History of cirrhotic decompensation within the past year
- Any other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the participant or would preclude the participant from successful study completion, including participant unable or unwilling to comply with the protocol requirements
- For individuals with known ATP7B genotype: individual does not have at least 1 ATP7B allele with either the p.H1069Q or p.R778L mutation
- Current participation in an investigational study for the treatment of WD
Where in United States
- University of Michigan MedicineAnn Arbor, United States
- Massachusetts General HospitalBoston, United States
- Northwestern UniversityChicago, United States
- University of California Los Angeles Medical CenterLos Angeles, United States
- Yale New Haven HospitalNew Haven, United States
- University of California Davis HealthSacramento, United States
- American Research CorporationSan Antonio, United States
About the trial
What the trial wants to find out
The aim of this study is to inform and improve future clinical trials in Wilson Disease (WD) by better understanding how patients with WD are living with and managing the disease, and by identifying key factors that shape their decisions to participate in clinical research.
The group in the trial
- Participants with at least 1 allele with the ATP7B p.H1069Q or p.R778L mutation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prescreening Study to Identify Potential Participants for a Clinical Study in Wilson Disease (WD) Due to the ATP7B p.H1069Q or p.R778L Mutations
- Record updated
- 12 May 2026